Ursolic acid alleviates lupus nephritis by suppressing SUMO1-mediated stabilization of NLRP3.

Autor: Chen L; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China., Li F; Dermatology Department Huashan Hospital, Fudan University, Shanghai, China., Ni JH; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China., Hao YX; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China., Feng G; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China., Shen XY; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China; Shanghai Fifth People's Hospital, Fudan University, Shanghai, China; Minhang Hospital, Fudan University, Shanghai, China. Electronic address: shxiaoy@fudan.edu.cn., You Y; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China; Shanghai Fifth People's Hospital, Fudan University, Shanghai, China; Minhang Hospital, Fudan University, Shanghai, China. Electronic address: yyou@fudan.edu.cn.
Jazyk: angličtina
Zdroj: Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2024 Jul 25; Vol. 130, pp. 155556. Date of Electronic Publication: 2024 Mar 20.
DOI: 10.1016/j.phymed.2024.155556
Abstrakt: Background: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease that affects multiple organs and cause a wide range of severe clinical manifestations, including lupus nephritis (LN), which is a major risk factor for morbidity and mortality in individual with SLE. Ursolic acid (UA) is a natural compound with favorable anti-inflammatory properties and has been employed to treat multiple disease, including inflammatory diseases, diabetes, and Parkinson's disease. However, its therapeutic potential on LN and the underlying mechanisms remains unclear.
Purpose: This aim of this study was to investigate the impact of UA on LN and its underlying mechanism.
Methods: MRL/lpr lupus-prone mouse model was used and UA was administered orally for 8 weeks. Dexamethasone was used as a positive control. After 8 weeks of administration, the spleen-to-body-weight ratio, renal function, urine albumin excretion, cytokines levels, and the deposition of immune complex were measured. The primary mouse glomerular mesangial cells (GMCs) and SV40-MES-13 were stimulated by lipopolysaccharide (LPS), either alone or in combination with nigericin, to establish an in vitro model. The activation of NLRP3 inflammasome were investigated both in vivo and in vitro using qRT-PCR, immunoblotting, and immunofluorescence.
Results: Our results revealed that UA prominently alleviated LN in MRL/lpr lupus-prone mice, leading to a significant reduction in proteinuria production, infiltration of immune cells infiltration, and histopathological damage in the renal tissue. In addition, UA exerted inhibitory effects on the secretion of IL-1β, IL-18, and caspase-1, pyroptosis, and ASC speck formation in primary mouse GMCs and SV40-MES-13 cells. Furthermore, UA facilitated the degradation of NLRP3 by suppressing SUMO1-mediated SUMOylation of NLRP3.
Conclusion: UA possess a therapeutical effect on LN in MRL/lpr mice by enhancing the degradation of NLRP3 through inhibition of SUMO1-mediated SUMOylation of NLRP3. Our findings provide a basis for proposing UA as a potential candidate for the treatment of LN.
Competing Interests: Declaration of competing interest All authors declare no conflict of interest.
(Copyright © 2024 Elsevier GmbH. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: